

**Table (1) Patients characteristic in concomitant and sequential boost groups**

Variable	Concomitant boost N=24	Sequential boost N=24	P value
<b>Age/years</b> Mean ± SD Median (range)	45.92±7.37 46 (27-60)	50.17±10.82 51 (33-65)	0.12
<b>Site</b> Right Left	13 (54.17%) 11 (45.83%)	7 (29.17%) 17 (70.83%)	0.08
<b>Quadrant</b> Lower inner Lower outer Supra areolar Upper inner Upper outer	4 (16.67%) 2 (8.33%) 3 (12.50%) 1 (4.17%) 14 (58.33%)	2 (8.33%) 7 (29.17%) 1 (4.17%) 4 (16.67%) 10 (41.67%)	0.14
<b>Pathology</b> IDCA	24 (100%)	24 (100%)	1.00
<b>Tumor grade</b> 2 3	22 (91.67%) 2 (8.33%)	23 (95.83%) 1 (4.17%)	1.00
<b>Tumor size</b> Mean ± SD Median (range)	2.70±0.77 2.75 (1.5-4)	2.66±0.79 2.5 (1-4)	0.85
<b>Number of positive LN</b> Mean ± SD Median (range)	1 ±1.28 0 (0-3)	1.25 ±1.26 1 (0-3)	0.47
<b>Number of removed LN</b> Mean ± SD Median (range)	22.08±6.20 22 (12-39)	16.29±5.66 14 (6-25)	0.003
<b>Estrogen receptors</b> Negative Positive	5 (20.83%) 19 (79.17%)	8 (33.33%) 16 (66.67%)	0.33
<b>Progesterone receptors</b> Negative Positive	7 (29.17%) 17 (70.83%)	8 (33.33%) 16 (66.67%)	0.76
<b>HER2</b> Negative Positive	17 (70.83%) 7 (29.17%)	17 (70.83%) 7 (29.17%)	1.00

**Table (2) skin toxicity in concomitant and sequential radiotherapy boost groups**

Variable	Concomitant boost N=24	Sequential boost N=24	P value
<b>Acute skin toxicity</b>			
G0	8 (33.33%)	4 (16.67%)	0.18
G1 dry desquamation	10 (41.67%)	6 (25.00%)	
G1 mild erythema	3 (12.50%)	3 (12.50%)	
G2 tender erythema	2 (8.33%)	4 (16.67%)	
G3 moist desquamation	1 (4.17%)	6 (25.00%)	
G4 ulceration	0	1 (4.17%)	
<b>Late skin toxicity 12ms</b>			
G0	8 (33.33%)	5 (20.83%)	0.19
G1	5 (20.83%)	3 (12.50%)	
G2	10 (41.66%)	16(66.67%)	
G3	1 (4.17%)	0	
<b>Late skin toxicity 24ms</b>	N=22	N=22	
G0	16 (72.73%)	14 (54.55%)	0.24
G1	2 (9.09%)	7 (31.82%)	
G2	4 (18.19%)	3 (13.64%)	

**Table (3) lung and heart toxicity in concomitant and sequential radiotherapy boost groups**

Variable	Concomitant boost N=24	Sequential boost N=24	P value
<b>Acute lung toxicity</b>			
G0	23 (95.83%)	23 (95.83%)	1.00
G2 cough dyspnea	1 (4.17%)	1 (4.17%)	
<b>Late lung toxicity</b>			
G0	23 (95.83%)	21 (87.50%)	0.30
G3 dense radiograph	1 (4.17%)	3 (12.50%)	
<b>Heart toxicity</b>			
No	22 (91.67%)	20 (83.33%)	0.38
Yes	2 (8.33%)	4 (16.67%)	

**Table (4) Arm lymphedema in concomitant and sequential radiotherapy boost groups**

Variable	Concomitant boost N=24	Sequential boost N=24	P value
<b>Arm lymphedema before RT</b>			
G0	22 (91.67%)	24 (100%)	0.15
G1 mild lymphedema	2 (8.33%)	0	
<b>Arm lymphedema after12 ms of RT</b>			
G0	19 (79.17%)	22 (91.67%)	0.24
G1 mild lymphedema	2 (8.33%)	1 (4.17%)	
G2 moderate lymphedema	3 (12.50%)	1 (4.17%)	
<b>Arm lymphedema after24 ms of RT</b>	N=22	N=22	
G0	21 (95.45%)	21 (95.45%)	0.37
G2 moderate lymphedema	1 (4.55%)	0	
G3 severe lymphedema	0	1 (4.55%)	

